SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Battalion Oil Corp. engages in the acquisition, production, exploration, and development of liquids-rich oil and natural gas assets in the Delaware Basin. The company was founded in 1987 and is headquartered in Houston, TX.

Battalion Oil Corp - Ordinary Shares (New)

Battalion Oil Corp. is experiencing a massive surge, fueled by escalating geopolitical tensions, a sharp rise in oil prices, and widespread reports of a closed Strait of Hormuz. The community is actively discussing its low float and the potential for a significant short squeeze, anticipating further multi-day gains for the energy stock.

Indonesia Energy Corp. Ltd. operates as an oil and gas, exploration, and production company. It engages in oil and gas assets portfolio with a mix between medium-sized producing blocks and exploration blocks with significant resources. Its portfolio includes Kruh, Citarum, and Rangkas Area. The company was founded by James J. Huang and Wirawan Jusuf in 2014 and is headquartered in Jakarta, Indonesia.

Indonesia Energy Corp Ltd

Indonesia Energy is actively trending as escalating geopolitical tensions in the Middle East, including disruptions to key energy infrastructure and shipping routes, ignite fervent speculation across the oil and gas sector. The community is buzzing with comparisons to past parabolic runs during global conflicts, debating the stock's potential for a significant squeeze and sustained rally amid heightened volatility.

AST Spacemobile, Inc. engages in building a broadband cellular network in space to operate directly with standard, unmodified mobile devices based on an extensive IP and patent portfolio. It focuses on providing mobile broadband services with global coverage to all end-users, without the need to purchase special equipment. The company was founded by Abel Avellan on May 31, 2017 and is headquartered in Midland, TX.

AST SpaceMobile Inc - Ordinary Shares - Class A

AST SpaceMobile Inc

AST SpaceMobile is a major discussion point as investors await its earnings call for critical updates on satellite deployment and commercialization guidance, following significant new partnerships to expand its direct-to-device connectivity across Europe and Asia. The community remains divided between high conviction in the long-term disruptive technology and concerns over execution and profitability in this capital-intensive sector.

Credo Technology Group Holding Ltd. engages in the development of connectivity solutions and products for the data infrastructure market. Its products include integrated circuits, active electrical cables, and SerDes chiplets. The company was founded by Chi Fung Cheng and Yat Tung Lam on 2008 and is headquartered in George Town, Cayman Islands.

Credo Technology Group Holding Ltd

Credo Technology is trending following a significant pre-announcement of Q3 revenue far exceeding guidance and implying massive year-over-year growth, driven by strong demand in AI data center infrastructure. The community is actively debating whether this signals a strong post-earnings rally, especially given soaring hyperscaler CapEx and a new "Buy" rating from Goldman Sachs, or if the stock's recent volatility and prior "sell the news" patterns will persist.

Gorilla Technology Group, Inc. engages in the provision of video intelligence, Internet of Things (IoT) security, edge AI data analytics, and operational technology security solutions and services in Asia Pacific. It operates through the following segments: Video IoT, Security Convergence, and Other. The company was founded by Spincer Koh in May 2001 and is headquartered in London, the United Kingdom.

Gorilla Technology Group Inc

Gorilla Technology Group is trending as investors eagerly await its upcoming Fiscal Year 2025 earnings, with the community anticipating strong financial results and a potential short squeeze. Recent news of the company's acquisition of a regulated financial platform for non-dilutive AI infrastructure project financing is also a key talking point, fueling optimism for its long-term growth as an AI infrastructure giant.

Archer Aviation, Inc. engages in the development of electric vertical take-off and landing (eVTOL) aircraft. The company was founded by Brett Adcock and Adam Goldstein on October 16, 2018, and is headquartered in San Jose, CA.

Archer Aviation Inc - Ordinary Shares - Class A

Archer Aviation Inc

Archer Aviation is drawing significant attention after achieving an Airworthiness Certificate for its N704AX aircraft, paving the way for piloted VTOL testing, alongside a Starlink partnership and UK defense expansion; this operational progress has sparked a divided community sentiment ahead of its upcoming earnings.

MongoDB, Inc. engages in the development and provision of a general-purpose database platform. The firm's products include MongoDB Enterprise Advanced, MongoDB Atlas, and Community Server. It also offers professional services including consulting and training. The company was founded by Eliot Horowitz, Dwight A. Merriman, Kevin P. Ryan, and Geir Magnusson Jr. in November 2007 and is headquartered in New York, NY.

MongoDB Inc - Ordinary Shares - Class A

MongoDB Inc

MongoDB is experiencing a sharp rally following a strong earnings beat and raised full-year guidance, fueled by robust Atlas cloud adoption and significant AI workload growth, prompting analysts to upgrade price targets while some in the community debate its current valuation.

AeroVironment, Inc. engages in the design, development, and production of multi-domain robotic systems and related services for government agencies and businesses. It operates through the following business segments: UnCrewed Systems, Loitering Munitions Systems, and MacCready Work. The UnCrewed Systems segment focuses primarily on small UAS products designed to operate reliably at lower altitudes in a wide range of environmental conditions. The Loitering Munitions Systems segment focuses primarily on tube-launched aircraft that deploy with the push of a button, fly at higher speeds than small UAS products, and perform either effects delivery or reconnaissance missions, and related support services including training, spare parts, product repair, and product replacement. The MacCready Works segment focuses on customer-funded research and development in the areas of HAPS, robotics, sensors, software analytics, data intelligence, and connectivity. The company was founded by Paul B. MacCready, Jr. in July 1971 and is headquartered in Arlington, VA.

AeroVironment Inc.

AeroVironment is experiencing extreme volatility and a sharp sell-off following a Raymond James downgrade and news that the US Space Force is re-competing a major contract, sparking intense community debate on whether the market reaction is overdone given robust demand for drone technology.

SoFi Technologies, Inc. is a financial service platform, which engages in the provision of student loan refinancing options to the private student loan market. It operates through the following segments: Lending, Technology Platform, and Financial Services. The Lending segment offers personal loans, student loans, home loan products, and related servicing activities. The Technology Platform segment focuses on technology products and solutions revenue. The Financial Services segment includes the SoFi Money product, SoFi Invest product, SoFi Credit Card product, SoFi Relay personal finance management product, and other financial services such as lead generation and content for other financial services institutions. The company was founded in 2011 and is headquartered in San Francisco, CA.

SoFi Technologies Inc

SoFi is trending as CEO Anthony Noto's significant share purchase ignites community optimism, with many viewing it as a strong bullish signal and eagerly anticipating potential S&P 500 inclusion news for the fintech company.

SSgA Active Trust - State Street SPDR S&P 500 ETF Trust

SPY is heavily discussed as it defies escalating geopolitical tensions with Iran and the reported closure of the Strait of Hormuz, showcasing surprising resilience that has frustrated bearish expectations while bulls celebrate the "stonks only go up" phenomenon.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

<ul class="summary-bullets"><li>The clearance allows the clinical-stage biotech firm to move ahead with preparations for a planned Phase 1b registrational study.</li><li>Serina&nbsp;had previously received written feedback from the agency supporting its proposed registrational trial design under an NDA pathway.</li><li>The latest update follows a setback in November 2025, when the FDA placed a clinical hold on the application to initiate clinical trials.</li></ul>Shares of Serina Therapeutics (SER) surged more than 70% in pre-market trading on Thursday after the company announced that the U.S. Food and Drug Administration (FDA) cleared its Investigational New Drug (IND) application for SER-252, a therapy to treat patients with Parkinson’s disease.SER-252 is an experimental apomorphine-based therapy to provide continuous dopaminergic stimulation, an approach shown to ease levodopa-related motor complications such as dyskinesia in people with Parkinson’s disease.<a href="https://stocktwits.com/symbol/SER">SER stock</a> had surged nearly 35% in after-hours trading on Wednesday.<h2 class="st-heading-2">SER-252: What Next?</h2>The clearance allows the clinical-stage biotech firm to move ahead with preparations for a planned Phase 1b registrational study in patients with advanced Parkinson’s disease. The IND clearance follows extensive regulatory engagement between Serina and the FDA.The company previously received written feedback from the agency supporting its proposed registrational trial design under an NDA pathway.“With FDA alignment on a registrational development strategy under a 505(b)(2) NDA pathway, we believe SER-252 has a clear and efficient path forward toward addressing a significant unmet medical need,” said Steve Ledger, Chief Executive Officer of Serina Therapeutics.The latest update follows a setback in November 2025, when the FDA placed a clinical hold on Serina’s application to initiate clinical trials. That hold was tied to a request for additional information related to an excipient in the drug’s formulation, a non-active substance included in a drug formulation alongside the active ingredient. Serina emphasized that the FDA’s concerns did not involve SER-252’s active drug substance or its proposed mechanism of action.<h2 class="st-heading-2">Retail Reaction</h2>Retail sentiment on Stocktwits turned ‘extremely bullish’ from ‘bearish’ a day earlier, accompanied by ‘extremely high’ message volumes.<figure class="image"><img src="https://news.stocktwits-cdn.com/SER_jpg_f485987591.webp" alt="SER.jpg" width="927" height="114"><figcaption>SER's Sentiment Meter and Message Volumes in Premarket on Jan. 29, 2026 | Source: Stocktwits</figcaption></figure>One bullish user said the stock price could double with good volumes.<stembedurl>https://stocktwits.com/Targeted_Trading/message/643250368</stembedurl>Another user simply said “massive news”, and the stock could climb to $8. It is currently around $4.<stembedurl>https://stocktwits.com/madape/message/643249925</stembedurl>SER shares have shed more than 40% in the past year, though its year-to-date gains are over 25%.Read also: <a href="http://stocktwits.com/news-articles/markets/equity/nasdaq-sp500-futures-higher-meta-tsla-ser-mp-crml-stocks-to-watch/cmyidGCR4KJ">Nasdaq, S&amp;P 500 Futures Climb Ahead Of Apple Earnings: Why META, TSLA, MP, CRML, SER Are On Traders' Radar Today</a>For updates and corrections, email newsroom[at]stocktwits[dot]com

A candlestick chart can be seen in a trading platform on a smartphone. Top U.S. firms announced record buybacks this year. (Photo by Silas Stein/picture alliance via Getty Images)

Why Did SER Stock Surge Over 70% In Pre-Market Today?

The U.S. Food and Drug Administration cleared its Investigational New Drug application for SER-252, a therapy to treat patients with Parkinson’s disease.

SER Stock Surges Over 70% Pre-Market After FDA Clears Path For Parkinson’s Therapy

Equity

<ul class="summary-bullets"><li>Wall Street weighed heavy earnings and lingering government shutdown concerns.</li><li>Meta’s upbeat outlook offset Microsoft’s cloud slowdown, shifting focus to Apple’s earnings later today.</li><li>Commodities surged, with gold and silver hitting fresh record highs.</li></ul>U.S. stock futures were higher early Thursday as investors parsed the earnings report from the first of the “Magnificent Seven” companies (Meta, Microsoft, and Tesla), with the focus shifting to Apple, which reports earnings later today.&nbsp;As of 3:00 a.m. ET on Thursday, Nasdaq futures were up 0.4%, S&amp;P 500 futures gained 0.3%, while the Dow and Russell 2000 futures were flat.&nbsp;&nbsp;Meanwhile, retail sentiment toward the&nbsp;<a href="https://stocktwits.com/symbol/SPY">SPDR S&amp;P 500 ETF (SPY)</a>, an exchange-traded fund that tracks the S&amp;P 500 Index, and the&nbsp;<a href="https://stocktwits.com/symbol/QQQ">Invesco QQQ Trust (QQQ)</a> ETF, which tracks the Nasdaq 100 Index, remained ‘extremely bearish’, amid high message volumes.&nbsp;Precious metals continued to notch fresh records, with gold surging near $5600 and silver past $120.&nbsp;<a href="https://stocktwits.com/symbol/GLD/">SPDR Gold Shares ETF (GLD)</a> was the top trending ticker on Stocktwits at the time of writing. The&nbsp;<a href="https://stocktwits.com/symbol/SLV">iShares Silver Trust (SLV)</a> also saw retail sentiment remaining in the ‘extremely bullish’ territory, with ‘extremely high’ levels of chatter. Among base metals, copper prices too have surged 9% this month.Trending Stocks To WatchApple (AAPL): Investors will be watching for its earnings report after the market closes, with an eye on iPhone demand commentary and updates to its AI roadmap.Western Digital (WDC),&nbsp;SanDisk (SNDK): Watch out for these data storage giants as they report earnings today.Meta Platforms (META), Microsoft (MSFT):&nbsp;Meta stock surged in after-hours, driven by a strong sales forecast and a $100-billion AI investment plan. On the other hand, Microsoft tumbled due to slowing cloud growth and soft margin guidance.Tesla (TSLA): CEO Elon Musk confirmed plans to discontinue two EV models as it pivots to robotics. Tesla has also warned that capital expenditures could exceed $20 billion in 2026.Critical Minerals (MP, UAMY, TMC, USAR, CRML): U.S. miner stocks were under pressure amid reports that the Trump administration was considering shelving plans for minimum price floors. MP Materials was one of the first companies to&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/why-did-mp-uamy-tmc-usar-crml-stocks-dip-after-hours-today/cmyLvl0R40w">state</a> that the news was “inaccurate.”&nbsp;Carvana (CVNA): The stock plunged yesterday amid a high-profile short seller's accusations of overstated earnings.Alibaba (BABA): Its logistics arm reportedly plans to merge its autonomous driving unit with a Chinese ‘Robovan’ startup.Nvidia (NVDA):&nbsp;Faces renewed scrutiny after U.S. lawmakers raised concerns about its past involvement with China’s DeepSeek AI models.Home Depot (HD): Has announced layoffs of roughly 800 workers and mandated a full return to work-from-office.CRISPR Therapeutics (CRSP),&nbsp;Beam Therapeutics (BEAM):&nbsp;Cathie Wood’s ARK Investment Management has bought shares in these gene-editing stocks.Serina Therapeutics (SER): The stock surged in after-hours trading after the FDA cleared its Investigational New Drug (IND) application for a drug to treat advanced Parkinson’s disease.Other tickers trending on Stocktwits at the time of writing included ServiceNow (NOW), SoFi Technologies (SOFI), CrowdStrike Holdings (CRWD), and Novavax (NVAX), among others.&nbsp; Other Catalysts To Watch On the economic front, traders will monitor Initial Jobless Claims and the U.S. Trade Balance data today.And on the earnings radar, investors will also be watching for the quarterly reports from Mastercard (MA), Honeywell (HON), Caterpillar (CAT), and Comcast (CMCSA) before the markets open. After the close, investors will watch earnings from Visa, SAP, KLA, Deckers Brands, and Stryker, among others.For updates and corrections, email newsroom[at]stocktwits[dot]com

Nasdaq, S&P 500 Futures Climb Ahead Of Apple Earnings: Why META, TSLA, MP, CRML, SER Are On Traders' Radar Today

 Retail sentiment on major ETFs such as SPY and QQQ remains ‘extremely bearish’ on Stocktwits. 

<ul class="summary-bullets"><li>The agency has requested more information regarding an excipient in the formulation of SER-252, the company said.&nbsp;</li><li>The company said that it intends to work with the FDA to address its concerns. &nbsp;</li></ul>Shares of Serina Therapeutics (SER) slumped 7% in the pre-market session on Monday after the company announced that the U.S. Food and Drug Administration (FDA) had placed a clinical hold on its application to initiate clinical trials for its advanced Parkinson’s disease therapy candidate.The agency has requested more information regarding an excipient in the formulation of SER-252, the company said. An excipient is a substance, other than the active pharmaceutical ingredient (API), that is deliberately included in a drug formulation.Serina<a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://www.globenewswire.com/news-release/2025/11/03/3178999/0/en/Serina-Therapeutics-Provides-Regulatory-Update-on-SER-252-Program.html"> noted</a> that the agency’s feedback does not relate to its active drug substance or its proposed action mechanism.<h2 class="st-heading-2">What Are The Steps Forward?</h2>The company said that it intends to work with the FDA to address its concerns. Serina expects to receive the FDA’s formal clinical-hold letter within 30 days and provide an update once it has aligned with the agency on the next steps.<blockquote>“We appreciate the FDA’s engagement and constructive feedback. We will provide the additional information requested promptly as we continue to move forward in the registrational trial for SER-252.”&nbsp; -Steve Ledger, CEO, Serina Therapeutics.</blockquote>Board Member of Serina and Co-Founder and Executive Chairman of Juvenescence, Greg Bailey, has pledged to continue supporting the company financially and strategically in the initiation of clinical trials for SER-252. The registrational study of SER-252 is designed to evaluate the safety, tolerability, and pharmacokinetics of subcutaneous SER-252 compared to placebo, and will be conducted across sites in the U.S. and Australia.“This update does not change our conviction in Serina’s long-term potential or our belief in SER-252’s ability to meaningfully improve the lives of patients with advanced Parkinson’s disease,” he added.<h2 class="st-heading-2"> How Did Stocktwits Users React?</h2>On Stocktwits, retail sentiment around <a href="https://stocktwits.com/symbol/SER">SER stock</a> stayed within the ‘neutral’ territory over the past 24 hours, while message volume jumped from ‘normal’ to ‘high’ levels.SER stock is down 0.2% this year and approximately 22% over the past 12 months.&nbsp;Read also: <a href="https://stocktwits.com/news-articles/markets/equity/vertiv-bets-1-billion-on-ai-infrastructure-buys-liquid-cooling-firm-purge-rite/cL2NPfzR3za">Vertiv Bets $1 Billion On AI Infrastructure, Buys Liquid-Cooling Firm PurgeRite</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

Esperion’s stock (ESPR) has risen 40.5% so far in 2025. (Representative Image: Getty Images)

Serina Therapeutics Stock Slumps Pre-Market After FDA Places Hold On Application To Initiate Clinical Trials For Experimental Therapy

Serina noted that the agency’s feedback does not relate to its active drug substance or its proposed action mechanism.

Shares of Serina Therapeutics surged 37% in after-hours trading on Monday after the company said the U.S. Food and Drug Administration (FDA) supported advancing its Parkinson’s drug candidate SER-252 (POZ-apomorphine) into a registrational clinical program.The stock ended Monday’s session down 0.2% at $5.64, but surged 37.2% to $7.74 in after-hours trading following the FDA update.The FDA feedback followed a recent Type B meeting and paves the way for Serina to move forward with a streamlined regulatory strategy.“People living with advanced Parkinson’s need more consistent relief from motor fluctuations and our data to date suggest that SER-252 may reliably improve daily function,” CEO Steve Ledger said, adding that the company’s plan is designed to be both rigorous and capital efficient.The proposed program will leverage prior knowledge of apomorphine while incorporating Serina’s POZ-enabled profile. According to the FDA’s feedback, Serina’s first study could be designed as part of its overall registrational trial program, subject to final documentation at the time of IND submission.Serina plans to submit a U.S. IND application in the fourth quarter of 2025 and begin dosing patients in Australia later this year, with the data expected to feed into the global registrational package. U.S. patient enrollment is anticipated to begin in the first quarter of 2026, once the IND is cleared.The planned SER-252-1b study will test the therapy in up to 88 adults with Parkinson’s disease and motor fluctuations, evaluating safety, tolerability, pharmacokinetics, and exploratory efficacy measures, including MDS-UPDRS motor scores.SER-252 is designed to provide continuous dopaminergic stimulation (CDS) via once- or twice-weekly subcutaneous injections, utilizing Enable Injections’ enFuse wearable delivery platform to enhance patient comfort and convenience.&nbsp;Serina believes its POZ drug optimization technology can help stabilize drug levels and reduce side effects compared with traditional therapies.Ledger said the FDA’s response also validated Serina’s broader pipeline ambitions: “The feedback provides early proof-of-principle for our platform, confirming that we can effectively align with the agency’s expectations for the 505(b)(2) NDA pathway.”On Stocktwits, retail sentiment was ‘extremely bullish’ amid ‘extremely high’ message volume.One user suggested that Serina shares&nbsp;could continue to rise in the next session and said they were already “fully loaded.”<stembedurl>https://stocktwits.com/Santa34/message/626511634</stembedurl>Another user speculated whether Serina’s stock could reach $20 as soon as the next trading session.<stembedurl>https://stocktwits.com/darthttrader/message/626511005</stembedurl><a href="https://stocktwits.com/symbol/SER">Serina’s stock</a> has risen 12.6% so far in 2025.For updates and corrections, email newsroom[at]stocktwits[dot]com.

Serina’s stock (SER) has risen 12.6% so far in 2025. (Photo credit: Getty Images)

Why Did Serina Therapeutics Stock Rocket 37% After The Bell Today?

The FDA backed advancing its Parkinson’s drug candidate SER-252 into a registrational clinical program, a move that retail traders said could fuel further gains.

Shares of Serina Therapeutics, Inc. surged over 15% in pre-market trading on Tuesday, positioning the clinical-stage biotech&nbsp;stock to hit its highest level in over a month.&nbsp;The jump follows Serina’s announcement of a $10 million equity financing agreement with strategic shareholder JuvVentures (UK), aimed at propelling its SER-252 program for advanced Parkinson’s disease into clinical trials.Under the deal, Serina will issue one million shares of common stock at $10 per share, a significant 120% premium to its Nov. 26 closing price and a 110% premium from Monday’s closing price.The financing is structured in two tranches, with the first $5 million tranche already received on Nov. 27, and the second tranche due by Jan. 31, 2025.&nbsp;The funds will support the advancement of SER-252, an investigational therapy developed using Serina’s proprietary drug optimization technology.&nbsp;Designed to deliver continuous dopaminergic stimulation (CDS), SER-252 aims to mitigate levodopa-related motor complications, such as dyskinesia, while increasing “on time” and reducing “off time” in patients with advanced Parkinson’s disease.&nbsp;The therapy integrates a wearable drug delivery platform, which provides long-acting subcutaneous delivery of CDS without causing skin reactions, enhancing both comfort and convenience for patients.<figure class="image"><img style="aspect-ratio:1318/318;" src="https://st-everywhere-cms-prod.s3.us-east-1.amazonaws.com/SET_sentiment_and_message_volume_on_Dec_3_premarket_ebfe4d174b.png" alt="SET sentiment and message volume on Dec 3 premarket.png" width="1318" height="318"><figcaption>SET sentiment and message volume on Dec 3 premarket as of 8:00 am ET | source: Stocktwits</figcaption></figure>Retail investors were quick to rally behind the stock on Stocktwits, where sentiment turned ‘extremely bullish’ before the opening bell, with message volume surging.&nbsp;<stembedurl>https://stocktwits.com/harry925/message/594787799</stembedurl>Still, Serina’s stock remains down over 67% year-to-date,For updates and corrections, email newsroom[at]stocktwits[dot]com.Read next:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/tsla-stock-rises-after-upgrade-price-target-hikes/cJ9kq43RhE">Tesla Stock Rises After Massive Price Target Hikes On Trump, AI Factors: Retail’s Charged Up</a>

Under the deal, Serina will issue one million shares of common stock at $10 per share, a 110% premium from Monday’s closing price.

Serina Therapeutics Stock Soars Pre-Market On $10M Equity Deal To Fund Parkinson’s Trials: Retail Sentiment Explodes

The financing is structured in two tranches, with the first $5 million tranche already received on Nov. 27, and the second tranche due by Jan. 31, 2025. 

Serina Therapeutics, Inc. operates as a clinical-stage biotechnology company, which engages in the research and development of polymer technology. Its POZ technology is designed to optimize drug delivery to maximize compliance, therapeutic outcomes, safety, and quality of life for patients. It also offers drugs to treat neurological diseases, cancer, and pain. The company was founded by J. Milton Harris and Michael D. Bentley on March 26, 2024 and is headquartered in Huntsville, AL.

Serina Therapeutics Inc.

Beat EPS and revenue

Beat EPS, miss revenue

Miss EPS, beat revenue

Miss EPS and revenue

What do you expect from $MDB earnings today?

SER
Serina Therapeutics Inc.

Feed

News

Sentiment

Fundamentals

Info

Poll

Latest SER News

SERSerina Therapeutics Inc.